InvestorsHub Logo
Followers 26
Posts 2584
Boards Moderated 0
Alias Born 10/23/2003

Re: mikar post# 18530

Friday, 09/04/2020 9:52:22 AM

Friday, September 04, 2020 9:52:22 AM

Post# of 44690
You mean like this partnership - AbbVie will pay I-Mab USD 180 million in an upfront payment to exclusively license lemzoparlimab, along with USD 20 million in a milestone payment based on the phase 1 results, for a total of USD 200 million.